MedTrace Logo

Nutritional Assessment of Patients With Non-small Cell Lung Cancer Treated With Osimertinib

NCT07559526 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2026-04-30

No results posted yet for this study

Summary

Nutritional assessment of patients with non-small cell lung cancer treated with osimertinib.

Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is a leading cause of morbidity and mortality worldwide. Between 35% and 65% of NSCLC patients experience nutritional problems or malnutrition, which significantly affects their prognosis and quality of life. This study aims to describe the nutritional status and body composition of NSCLC patients treated with osimertinib, an oral tyrosine kinase inhibitor, while also assessing the prevalence of sarcopenia, presarcopenia, and dynapenia. Additionally, we explore the relationship between dose-limiting toxicities (DLTs) and nutritional status, as well as the impact of nutritional status on quality of life using the EQ-5D scale.

Conditions

  • Non-small-cell Lung Cancer
  • Sarcopenia
  • Quality of Life

Interventions

OTHER

Unic group

To describe the nutritional status and body composition of patients diagnosed with non-melanoma skin cancer (NMSC) treated with osimertinib in the Vigo health area. To evaluate the prevalence of sarcopenia in the study patients. To observe if there is a relationship between low muscle mass or malnutrition and the development of delayed-type hyperplasia (DTH) during osimertinib treatment.

Sponsors & Collaborators

  • Complejo Hospitalario Universitario de Vigo

    collaborator OTHER

  • Fundacin Biomedica Galicia Sur

    lead OTHER

Principal Investigators

  • Claudia Barca Díez · Galicia Sur Health Research Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-20
Primary Completion
2024-05-24
Completion
2024-07-12

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07559526 on ClinicalTrials.gov